Daniela Ampollini, Jul 27, 2012
The January 2012 decision of the Italian Antitrust Authority (“IAA”) in the Pfizer case, involving Pfizer’s actions to counter the marketing of generic versions of its product Xalatan, has given rise to a debate which has hardly appeased. Many commentators have already provided their impression from a competition law perspective. I, a patent lawyer, will try to provide mine, starting from the meaning and function of the patent law categories involved.
Links to Full Content
